SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (13392)10/7/2004 12:17:53 PM
From: scaram(o)uche  Respond to of 52153
 
>> Topol was basically suggesting a Phase IV to study cardiac effects in patients at risk of cardiac events <<

On the basis of results that were, in themselves, not adequately controlled.



To: Biomaven who wrote (13392)10/8/2004 7:30:34 PM
From: jayhawk969  Read Replies (1) | Respond to of 52153
 
The health insurers are going to benefit from this fallout as people dump the cox-2's and move to cheaper NSAID's and OTC Prilosec

Peter,I understand NSAID's but how does Prilosec treat arthritis?

J.D.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News